Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies

Human cytomegalovirus (HCMV) is an important pathogen in transplant patients and in congenital infection. Previously, we demonstrated that vaccination with a recombinant viral glycoprotein B (gB)/MF59 adjuvant formulation before solid organ transplant reduced viral load parameters post transplant. R...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Proc Natl Acad Sci U S A
Auteurs principaux: Baraniak, Ilona, Kropff, Barbara, Ambrose, Lyn, McIntosh, Megan, McLean, Gary R., Pichon, Sylvie, Atkinson, Claire, Milne, Richard S. B., Mach, Michael, Griffiths, Paul D., Reeves, Matthew B.
Format: Artigo
Langue:Inglês
Publié: National Academy of Sciences 2018
Sujets:
Biological Sciences
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6004462/
https://ncbi.nlm.nih.gov/pubmed/29686064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1800224115
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires